Search

Surender M Kharbanda

age ~67

from Natick, MA

Get Report
Also known as:
  • Surender Mohan Kharbanda
  • Surender M Kharband
  • Kharbanda M Surender
  • Surender A
Phone and address:
8 Jacqueline Cir, Natick, MA 01760
508-653-5154
Connected to:

Surender Kharbanda Phones & Addresses

  • 8 Jacqueline Cir, Natick, MA 01760 • 508-653-5154
  • Boston, MA
  • Wayland, MA
  • Brookline, MA
  • 8 Jacqueline Cir, Natick, MA 01760 • 508-241-7644

Education

  • Degree:
    Graduate or professional degree

Resumes

Surender Kharbanda Photo 1

Scientific Founder And Chief Scientific Officer

view source
Location:
450 Brookline Ave, Boston, MA 02215
Industry:
Hospital & Health Care
Work:
Nanoproteagen
President, Director and Chief Executive Officer
Linus Oncology
Founder and Director
Dana-Farber Cancer Institute
Senior Scientist
Genus Oncology Llc
Scientific Founder and Chief Scientific Officer
Ilex Oncology,Inc. Nov 2000 - Jun 2005
Vp, Head of Research
Education:
All India Institute of Medical Sciences 1979 - 1986
Doctorates, Doctor of Philosophy, Biochemistry, Philosophy
Skills:
Biotechnology
Surender Kharbanda Photo 2

Surender Kharbanda

view source
Surender Kharbanda Photo 3

Surender Kharbanda

view source
Location:
United States

Vehicle Records

  • Surender Kharbanda

    view source
  • Address:
    8 Jacqueline Cir, Natick, MA 01760
  • Phone:
    508-653-5154
  • VIN:
    WBXPC93417WF12016
  • Make:
    BMW
  • Model:
    X3
  • Year:
    2007

Us Patents

  • Modulation Of The Interaction Of Muc1 With Muc1 Ligands

    view source
  • US Patent:
    8129506, Mar 6, 2012
  • Filed:
    Oct 21, 2004
  • Appl. No.:
    10/577003
  • Inventors:
    Surender Kharbanda - Natick MA, US
    Donald W. Kufe - Wellesley MA, US
  • Assignee:
    Genzyme Corporation - Waltham MA
    Dana-Farber Cancer Institute, Inc. - Boston MA
  • International Classification:
    C07K 1/00
    C07K 14/00
    C07K 17/00
    C07K 16/00
    C12P 21/08
    A61K 39/00
  • US Classification:
    530395, 530362, 5303873, 5303877, 4241921
  • Abstract:
    The present invention provides for chimeric proteins comprising a MUC1 extracellular (MUC1-EC) polypeptide and a carrier polypeptide that function as traps for MUC1 ligands.

  • Muc-1 Cytoplasmic Domain Peptides As Inhibitors Of Cancer

    view source
  • US Patent:
    8524669, Sep 3, 2013
  • Filed:
    Oct 16, 2009
  • Appl. No.:
    12/580865
  • Inventors:
    Donald W. Kufe - Wellesley MA, US
    Surender Kharbanda - Natick MA, US
  • Assignee:
    Dana-Farber Cancer Institute, Inc. - Boston MA
    Genus Oncology, LLC - Vernon Hills IL
  • International Classification:
    A61P 35/00
  • US Classification:
    514 193, 514 65
  • Abstract:
    The invention provides for peptides from the Mucin 1 (MUC1) cytoplasmic domain and methods of use therefor. These peptides can inhibit MUC1 oligomerization, thereby preventing tumor cell growth, inducing tumor cell apoptosis and necrosis of tumor tissue in vivo.

  • Inhibition Of Inflammation Using Antagonists Of Muc1

    view source
  • US Patent:
    8614186, Dec 24, 2013
  • Filed:
    May 27, 2010
  • Appl. No.:
    12/789127
  • Inventors:
    Donald W. Kufe - Wellesley MA, US
    Surender Kharbanda - Natick MA, US
  • Assignee:
    Dana-Farber Cancer Institute, Inc. - Boston MA
    Genus Oncology, LLC. - Chicago IL
  • International Classification:
    A61K 38/00
    A61P 29/00
  • US Classification:
    514 122
  • Abstract:
    The invention provides for peptides from the MUC1 cytoplasmic domain and methods of use therefor. These peptides can inhibit MUC1 oligomerization, inhibit the interaction of MUC1 with NF-κB or a STAT, and block inflammatory response mediated by NF-κB or STAT signaling.

  • Tumor Chemopotentiation Using Isocoumarin Derivatives

    view source
  • US Patent:
    20020165210, Nov 7, 2002
  • Filed:
    Feb 23, 2002
  • Appl. No.:
    10/082521
  • Inventors:
    Naoki Agata - Brookline MA, US
    Surender Kharbanda - Natick MA, US
  • International Classification:
    A61K031/57
    A61K031/7048
    A61K031/704
    A61K031/4745
    A61K031/366
    A61K031/66
  • US Classification:
    514/171000, 514/179000, 514/027000, 514/034000, 514/110000, 514/283000, 514/457000
  • Abstract:
    A method for enhancing the efficacy of chemotherapy in the treatment of cancer in animals, particularly humans, is provided wherein isocoumarin derivatives that exhibit unique chemopotentiation properties are employed in a combination treatment with chemotherapy.

  • Muc1 Interference Rna Compositions And Methods Derived Therefrom

    view source
  • US Patent:
    20040018181, Jan 29, 2004
  • Filed:
    May 29, 2003
  • Appl. No.:
    10/447839
  • Inventors:
    Donald Kufe - Wellesley MA, US
    Surender Kharbanda - Natick MA, US
    Steven Weitman - San Antonio TX, US
  • International Classification:
    C12Q001/68
    C07H021/02
    A61K048/00
  • US Classification:
    424/093210, 514/044000, 435/006000, 536/023100
  • Abstract:
    The present invention provides compositions and methods for inhibiting the proliferation of cancer cells and for the treatment of tumors with antagonists of the binding of ligands to the extracellular domain of MUC1, such binding being related to an oncogenic function of MUC1, and by compositions that downregulate the expression of MUC1.

  • Muc1 Antagonist Enhancement Of Death Receptor Ligand-Induced Apoptosis

    view source
  • US Patent:
    20070202134, Aug 30, 2007
  • Filed:
    Feb 22, 2005
  • Appl. No.:
    10/598295
  • Inventors:
    Donald Kufe - Wellesley MA, US
    Surender Kharbanda - Natick MA, US
  • International Classification:
    A61K 39/00
    A61P 43/00
    C12N 5/06
    C12N 5/08
  • US Classification:
    424277100, 435375000
  • Abstract:
    The present invention relates to methods of enhancing death receptor-induced apoptosis in MUC1 expressing cells comprising contacting the MUC1 expressing cells with an effective amount of a MUC1 antagonist.

  • Modulation Of Muc1 Mediated Signal Transduction

    view source
  • US Patent:
    20080090770, Apr 17, 2008
  • Filed:
    Apr 12, 2004
  • Appl. No.:
    10/553028
  • Inventors:
    Michael P. Belmares - San Jose CA, US
    Peter S. Lu - Mountain View CA, US
    Jonathan David Garman - San Jose CA, US
    Albert A. Jecminek - San Antonio TX, US
    Surender Kharbanda - Natick MA, US
    Naoki Agata - Brookline MA, US
    Donald W. Kufe - Wellesley MA, US
  • International Classification:
    A61K 38/08
    A61K 38/06
  • US Classification:
    514 17, 514 18
  • Abstract:
    The present invention provides compositions and methods for inhibiting the binding of the carboxy-terminus of MUC1 to PDZ domain(s) and to enhance the sensitivity of MUC1 expressing cancer cells to chemotherapeutic agents.

  • Small Molecule Inhibitors Of Muc1 And Methods Of Identifying The Same

    view source
  • US Patent:
    20110251246, Oct 13, 2011
  • Filed:
    Mar 10, 2011
  • Appl. No.:
    13/045033
  • Inventors:
    Donald W. Kufe - Wellesley MA, US
    Surender Kharbanda - Natick MA, US
  • International Classification:
    A61K 31/427
    C12Q 1/18
    G01N 21/64
    G01N 21/76
    C12Q 1/68
    C12N 5/071
    C12N 5/09
    A61K 31/353
    A61K 31/4178
    A61K 31/4155
    A61P 35/00
    C12N 5/0786
    C12N 5/0781
    C12N 5/0783
    C12N 5/0784
    C12N 5/0787
    G01N 27/447
    G01N 33/68
    B82Y 15/00
  • US Classification:
    514365, 436501, 435 32, 435 79, 435 617, 435375, 514456, 514397, 514406, 204456, 977773, 977904
  • Abstract:
    The invention provides methods for the identification of small molecules that inhibit MUC1 oligomerization, and the functions flowing therefrom. In addition, small molecules that prevent MUC1 oligomerization are disclosed. Identified molecules will find use in treating a variety of MUC1-related inflammatory conditions, including MUC1-related cancers.
Get Report for Surender M Kharbanda from Natick, MA, age ~67
Control profile